Summary
Becton Dickinson and Company (BDX) reported its first-quarter results for fiscal year 2001, ending March 31, 2001. The company demonstrated modest revenue growth, with an increase of 4% for the quarter, reaching $961.2 million. This growth was primarily driven by strong performance in the Biosciences segment, which saw a 10% revenue increase. However, unfavorable foreign currency translation negatively impacted reported revenues by approximately $31 million for the quarter. Net income for the quarter was $118.4 million, a slight decrease from $119.2 million in the prior year, resulting in diluted earnings per share of $0.44, down from $0.45 in the same period last year. While revenue growth was somewhat constrained by currency headwinds and a decrease in high-margin flu product sales within the Clinical Lab segment, the company continues to manage its expenses effectively, with selling and administrative costs as a percentage of revenue declining. BDX also highlighted progress in its restructuring efforts and ongoing investment in new product development, positioning for future growth.
Key Highlights
- 1Total revenues increased by 4% to $961.2 million for the three months ended March 31, 2001, compared to $925.1 million in the prior year.
- 2Net income for the quarter was $118.4 million, a slight decrease from $119.2 million in the prior year.
- 3Diluted earnings per share were $0.44 for the quarter, down from $0.45 in the prior year.
- 4The Biosciences segment showed robust revenue growth of 10% for the quarter.
- 5Foreign currency translation unfavorably impacted revenues by an estimated $31 million for the quarter.
- 6The company's debt-to-capital ratio improved to 38.9% as of March 31, 2001, down from 45.1% a year prior.
- 7BDX completed the acquisition of Gentest Corporation on January 10, 2001, for approximately $29 million.